Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Abella
  NCT04329923		 hydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)NA
65/65 safety concern
  • inconclusive 6 % increase in conversion to SARS-CoV- 2–positive status via NP swab (PE)
  • statistically significant 1.3-fold increase in conversion to SARS-CoV- 2–positive status via NP swab
EPICOS (Polo) RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
231/223 inconclusive
    HERO-HCQ (Naggie)
          NCT04334148    		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
    		683/676 inconclusive
      Rojas-Serrano
              NCT04318015      		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
      		65/65 inconclusive
      • inconclusive 84 % decrease in symptomatic Covid-19,infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
      Seet (HCQ)
              NCT04446104      		 RCThydroxychloroquinevitamin CCOVID-19 prophylaxis (excluding children)high
      		432/619 suggested
        Syed
                  NCT04359537        		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)high
        		154/46 safety concern
        • statistically significant 1.6-fold increase in infection (PCR positive symptomatic or not) but with a low degree of certainty due to high risk of bias
        Barnabas RV
                  NCT04328961        		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)low
        		407/422 safety concern
        • inconclusive 10 % increase in infection (PCR positive symptomatic or not) (PE) with a high degree of certainty due to low risk of bias
        • statistically significant 58 % increase in adverse events with a high degree of certainty due to low risk of bias
        BCN PEP-CoV-2-Study 1 (Mitja NEJM)
                  NCT04304053        		 RCThydroxychloroquinestandard of careCOVID-19 prophylaxis (excluding children)some concern
        		1116/1198 safety concern
        • inconclusive 14 % decrease in infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • statistically significant 19.3-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
        COVID PREP HCQ (2x week, Rajasingham)
                  NCT04328467        		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)low
        		495/494 safety concern
        • inconclusive 26 % decrease in infection (PCR positive symptomatic or not) (PE) with a high degree of certainty due to low risk of bias
        • statistically significant 1.0-fold increase in adverse events with a high degree of certainty due to low risk of bias
        COVID-PEP-Post exposure (Boulware)
                  NCT04308668        		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)low
        		414/407 safety concern
        • statistically significant 2.3-fold increase in adverse events with a high degree of certainty due to low risk of bias
        Grau-Pujol
                  NCT04331834        		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)high
        		142/127 inconclusive
          PATCH-cohort 3 PreP (Abella)
                      NCT04329923          		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
          		66/66 inconclusive
          • inconclusive 5 % decrease in infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
          1 study excluded by filtering options (0 RCT / 1 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

           

          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons